Global Vision
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.
In 2023, China emerged as the second largest exporter in the global biopharmaceutical pipeline. While innovation, international expansion, and commercialization remain pivotal, the industry's growth has increasingly relied on industrial efforts due to less active capital markets.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a Citeline White Paper shows.
The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.
India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?
As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.
While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
A public interest group has accused the pharma major of using excessive pricing to bolster sales of blockbuster Humira, consequently damaging the health of Dutch patients.
APrevent, a laryngeal implant developer from Taiwan, was named the overall winner of the annual MedTech Innovator APAC accelerator award for 2024. Awards managing director Fredrik Nyberg talked to In Vivo about the rising importance of the APAC region’s hub of companies providing innovative medtech.
The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.
New rules on health technology assessments in Spain make room for real-world evidence and early dialog.
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.
With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends.